The Living Wage Foundation recognises and celebrates the leadership shown by Living Wage Employers across the UK. We believe that work should be the surest way out of poverty.
ELITE is a programme of structured engagement developing and supporting ambitious private companies through their next stage of growth. Partnered with Imperial College Business School ELITE delivers a three part service of education, business support, mentoring and access to an ecosystem of professionals fostering growth and innovation.
Tissue Solutions are a member of the Institute of Export, the professional membership body representing and supporting the interests of everyone involved in importing, exporting and international trade. The Institute is the leading authority in best practice and competence for businesses trading globally.
Tissue Solutions belongs to the BIA, a trade association for innovative enterprises in the UK’s bioscience sector. As the voice of UK bioscience, the association is active in representing the sector and its needs to audiences, from patient groups to regional, national and pan-European governments.
Tissue Solutions is also a member of ISBER, an international society for people interested in the biobanking of human and non-human biological materials. ISBER was formed 11 years ago by members of the US National Institutes of Heath and Centers for Disease Control and it is based in Bethesda, Maryland. It is a very active society with many committees and working groups.
Tissue Solutions is a member of EATB. The aims of the European Association of Tissue Banks is to produce important standards, contributions to consultations leading to regulation of the field of tissue banking throughout Europe; to cooperate with national associations of tissue banking and with those in other countries.
Tissue Solutions is an active member of ESBB and our COO, Dr Ann Cooreman, is one of the founding members of the organisation. The mission of ESBB is to advance the field of biobanking in support of research relating to healthcare, education and the environment. It is an independent European chapter of ISBER. It works in collaboration with ISBER and also with other groups such as BBMRI, to avoid any duplication of effort and wherever possible to assist the work of this important pan-European biobanking infrastructure project. Similarly, it will be desirable for ESBB to support the associated Global Biological Resource Centre Network project (GBRCN) which is developing in parallel to the BBMRI and focusing initially on the microbial domain.
The HTA license and inspect organisations that store and use human tissue for purposes such as research, patient treatment, post-mortem examination, teaching and public exhibitions.
The EU Tissues and Cells Directive sets standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissue and cells intended for human application. It was adopted by the European Parliament on 7th April 2004.
FDA is the federal agency responsible for ensuring that foods are safe, wholesome and sanitary; human and veterinary drugs, biological products, and medical devices are safe and effective; cosmetics are safe; and electronic products that emit radiation are safe. FDA also ensures that these products are honestly, accurately and informatively represented to the public.
The European Medicines Agency (EMEA) is a decentralized body of the European Union with headquarters in London. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.
The Medical Research Council provides guidance to help our scientists to implement good practice and meet legal and ethical requirements.
The British Association for Tissue Banking (BATB) was formed in 1992 in response to the growing clinical need for human tissue for transplantation.
Research Ethics Committees (RECs) safeguard the rights, safety, dignity and well-being of people participating in research in the National Health Service.
The National Cancer Institute (NCI), through its Office of Biorepositories and Biospecimen Research (OBBR), is leading a national initiative to systematically address and resolve one of the most difficult problems that will drive 21st century cancer research: the limited availability of carefully collected and controlled, high-quality human biospecimens annotated with essential clinical data and properly consented for broad investigational use.
The Office for Human Research Protections (OHRP) provides leadership in the protection of the rights, welfare, and wellbeing of subjects involved in research conducted or supported by the U.S. Department of Health and Human Services (HHS).
The Queen’s Awards for Enterprise: International Trade 2014
The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule is the first comprehensive Federal protection for the privacy of personal health information. Research organizations and researchers may or may not be covered by the HIPAA Privacy Rule. This website provides information on the Privacy Rule for the research community.
OBN is the not-for-profit Membership organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Member companies are located across the Golden Triangle and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland, benefiting from networking, partnering, purchasing, training, advising and advocacy activities.
Tissue Solutions is a member of The European Biotechnology Network, a group dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.
The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.
The Medicines Discovery Catapult is a national centre of applied Research and Development expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects. It is one of a network of elite, not-for-profit technology and innovation centres established by Innovate UK as a long-term investment in the UK’s economy. The Medicines Discovery Catapult will work with industry, academic teams, technology experts, charities, regulators and others, to develop new approaches for the discovery and early development of new medicines helping to transform ideas into commercial products and services for the wider health and wealth of the country. By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, it can help the UK maintain its heritage position as a global leader in this key industry.